Romosozumab, a monoclonal antibody to sclerostin, is a new osteoanabolic drug that increases bone formation and decreases bone resorption, which is recommended as preliminary treatment in patients with a very high fracture risk without a history of stroke or myocardial infarction (92). This evidence concerns the gene SOST and myocardial infarction.